Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2223 + Penpulimab in advanced hepatocellular carcinoma
NCT06320080Phase 1Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2024
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bemipalimab in hepatocellular carcinoma (HCC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Objective Response Rate at 100 weeks and Progression-Free Survival at 100 weeks. Started May 2024; status: terminated.
02
Drugs
bemipalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06320080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06320080.